Currently out of the existing stock ratings of Tim Chiang, 75 are a BUY (88.24%), 9 are a HOLD (10.59%), 1 are a SELL (1.18%).

Tim Chiang

Work Performance Price Targets & Ratings Chart

Analyst Tim Chiang, carries an average stock price target met ratio of 31.35% that have a potential upside of 19.28% achieved within 236 days. Previously, Tim Chiang worked at CAPITAL ONE, BTIG, NORTHLAND CAPITAL MARKETS.

Tim Chiang’s has documented 185 price targets and ratings displayed on 16 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on IRWD, Ironwood Pharmaceuticals at 02-Sep-2022.

Wall Street Analyst Tim Chiang

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/15/2018. The price target of $120 was fulfilled within 4 days with a profit of $17.71 (17.31%) receiving and performance score of 43.28.

Average potential price target upside

of $17.01 (13.96%) on SRPT (SAREPTA THERAPEUTICS).
of $12.38 (77.56%) on IDYA (IDEAYA BIOSCIENCES).
of $11.97 (141.27%) on SMMT (SUMMIT THERAPEUTICS PLC).

AMPH Amphastar P EYEN Eyenovia IRWD Ironwood Pharmaceuticals MYL Viatris RLYP Relypsa SGYP Synergy Pharmaceuticals SRPT Sarepta Therapeutics TEVA Teva Pharma Industries Ltd ADR VTRS Viatris IDYA Ideaya Biosciences AMRX Amneal Pharmaceuticals, Common Stock ARDX Ardelyx CDTX Cidara Therapeutics SMMT Summit Therapeutics PLC PRGO Perrigo Company PLC PGNX Progenics Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jason Gerberry (BAML)